BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 28277851)

  • 21. Management of lower-risk myelodysplastic syndromes: the art and evidence.
    Komrokji RS; Sekeres MA; List AF
    Curr Hematol Malig Rep; 2011 Jun; 6(2):145-53. PubMed ID: 21442178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
    Volpe VO; Komrokji RS
    Ther Adv Hematol; 2021; 12():2040620720986641. PubMed ID: 33505645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS).
    Almeida A; Fenaux P; List AF; Raza A; Platzbecker U; Santini V
    Leuk Res; 2017 Jan; 52():50-57. PubMed ID: 27883945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Next-generation therapy for lower-risk MDS.
    Sébert M
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):59-64. PubMed ID: 38066862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2014 Jan; 89(1):97-108. PubMed ID: 24464505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How we manage adults with myelodysplastic syndrome.
    Fenaux P; Platzbecker U; Ades L
    Br J Haematol; 2020 Jun; 189(6):1016-1027. PubMed ID: 31568568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.
    Roberts DA; Steensma DP
    Curr Hematol Malig Rep; 2015 Sep; 10(3):318-28. PubMed ID: 26126600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
    Aul C; Giagounidis A; Germing U; Ganser A
    Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
    Garcia-Manero G; Chien KS; Montalban-Bravo G
    Am J Hematol; 2020 Nov; 95(11):1399-1420. PubMed ID: 32744763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2012 Jul; 87(7):692-701. PubMed ID: 22696212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of lenalidomide in the treatment of myelodysplastic syndromes.
    Komrokji RS; List AF
    Semin Oncol; 2011 Oct; 38(5):648-57. PubMed ID: 21943671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal sequencing of treatments for patients with myelodysplastic syndromes.
    Itzykson R; Fenaux P
    Curr Opin Hematol; 2009 Mar; 16(2):77-83. PubMed ID: 19468268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the Myeloid Lineages and the Immune Microenvironment in Myelodysplastic Syndromes: Novel and Evolving Therapeutic Strategies.
    Chung C
    Ann Pharmacother; 2022 Apr; 56(4):475-487. PubMed ID: 34330162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Laboratory and clinical risk assessment to treat myelodysplatic syndromes.
    Gidaro A; Deliliers GL; Gallipoli P; Arquati M; Wu MA; Castelli R
    Clin Chem Lab Med; 2016 Sep; 54(9):1411-26. PubMed ID: 26812791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline.
    Leitch HA; Buckstein R; Shamy A; Storring JM
    Crit Rev Oncol Hematol; 2013 Feb; 85(2):162-92. PubMed ID: 22901762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes.
    Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S39-43. PubMed ID: 27521322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Recent advances in the treatment of myelodysplastic syndromes].
    Gelsi-Boyer V; Vey N
    Rev Med Interne; 2006 Aug; 27(8):600-9. PubMed ID: 16713027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome.
    Battaglia MR; Cannova J; Madero-Marroquin R; Patel AA
    Curr Treat Options Oncol; 2024 May; ():. PubMed ID: 38814537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic approaches for the management of higher risk myelodysplastic syndromes.
    Wang C; Sallman DA
    Leuk Lymphoma; 2023 Mar; 64(3):511-524. PubMed ID: 36433645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.